It doesn’t take a rocket ― er, dick scientist ― to know that it’s not just whiskey that causes whiskey dick. Vodka drinkers ...
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease ...
AstraZeneca notes baxdrostat shows reduction in systolic blood pressure in phase III of uncontrolled or resistant hypertension: Our Bureau, Bengaluru Monday, January 5, 2026, 18:0 ...
Boehringer Ingelheim has unveiled its second kidney-focused collaboration in recent weeks, this time penning a ...
Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of ...
Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...
An announcement from Mineralys Therapeutics, Inc. ( ($MLYS) ) is now available. On January 6, 2026, Mineralys Therapeutics provided a corporate ...
Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of [68Ga]Ga-PentixaFor in treatment-resistant hypertension and Primary AldosteronismT ...
Stocktwits on MSN
CRNX stock gains, NBIX shares drop on positive results from genetics disorder trial
The trial was aimed at evaluating the efficacy, safety, and pharmacokinetics of Atumelnant when administered for 12 weeks in ...
Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.
Why cutting back on salt is important—but going too low may disrupt blood pressure, electrolytes and overall health.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback